PARTNERING OPPORTUNITY

Oxymo Technologies is completing an ambitious preclinical program. We are Phase I-II ready, with a strong IP position. We are seeking a major partnership.

THE GLOBAL HERPES PROBLEMATIC

  • 20 40 %
RHL affects 20–40% of the general population
  • 90 %
Herpes Simplex Viruses are common, affecting 90% (HSV-1) of general population (in North America)
  • 60 %
Herpes Simplex Viruses is common, affecting 60% (HSV-2) of general population (in North America)

INNOVATING FOR A GLOBAL MARKET

Herpes Simplex Viruses is common, affecting 90% (HSV-1) and 60% (HSV-2) of the general population (in North America). Patient suffering from labial or genital herpes, especially those affected by recurrent herpes (Recurrent Herpes Labialis or RHL), are desperate for a solution preventing the appearance of highly painful and contagious vesicles.

RHL affects 20–40% of the general population. Isolated or in clusters, RHL induced vesicles irremediably transform into oozing wounds lasting several days (7-14) and negatively impacting patient's quality of life.

RECENT NEWS

We will communicate shortly on our project.

For any inquiries please email